Isabel Chu

• Project Lead Scientist of mRNA/antibody program in infectious disease • Establish and maintain scientific relationships with CRO and academia o Manage antibody discovery campaign using Beacon technology. Responsible for antigen design, immunization strategy, functional assay design, Hit identification and Lead selection o Design and manage efficacy, PK/PD and biodistribution in vivo studies • Engineer bispecific, trispecific, biparatopic, IgA and IgM antibodies with improved in vitro and in vivo activity • Lead scientist responsible for due diligence of new mRNA technology • Submit 3 patent applications, quarterly project presentation to executives and ELN entry • Supervise a Senior Scientist

• Project Lead Scientist of three antibody discovery programs o Target validation, antigen design, immunization strategy, hit identification, lead selection and POC in vivo efficacy studies for an ADC and T-cell engager target o Developed functional high-throughput screens to distinguish agonist vs antagonist hits of a T-cell immune checkpoint inhibitor at the early hybridoma stage that resulted in a Lead agonist selection • Served as the scientific liaison with an external partner for 3 antibody-ADC programs • Designed and developed screening and reporter cell lines with retrovirus and lentivirus transductions leading to the successful early hit identification of functional antibodies • Supervised and trained one scientist and 2 summer interns • Managed antibody discovery CRO to explore new platforms • Prepared and presented projects to internal and external partners • Prepared study reports and data packages of therapeutic programs for external partners and produce data/report for patent application of an ADC target

• Design and coordinate immunization strategies with different teams resulting in the successful identification of hits of 2 different biologics programs • Stablish functional and binding assays for evaluating new targets by Flow cytometry and high-content-screening • Implement high-throughput ligand-blocking and internalization assays • Design and coordinate in vivo xenograft studies of an ADC target

• Validate targets originally identified by mass spectrometry for drug therapeutic potential • Design and develop immunogens for selected targets • Design and develop high-throughput screening methodologies to identify hits that showed desired phosphorylation modifications and desired functional activity • Optimize antibody generation platform, including immunization strategies and hit identification

• Reduced tumor growth in a triple negative breast cancer xenograft by promoting mesenchymal to epithelial (MET) differentiation via expression of the master transcription factor GATA3. • Generated an inducible BMI-1 animal model and identified novel phosphorylation sites of BMI-1 by mass spectrometry. • Initiated and supervised collaborations with investigators with mass spectrometry expertise and supervised the progression of numerous projects with collaborators.

• Identify mechanisms linking estrogen receptor (ER) proteolysis to the aggressive behavior of ER-negative breast cancer • Discovered a novel Src mediated p27 phosphorylation site that regulates p27 inhibitory function on cyclin E-cdk2 and mediates tamoxifen resistance in breast cancer • Resensitize tamoxifen resistant breast cancer cells utilizing Src (Saracatinib) and Erbb1/2 (Lapatinib) inhibitors • Led in the establishment of a newly constructed laboratory in Miami and trained new lab members after Dr. Slingerland moved her lab from Toronto to Miami in 2002 and I was the only lab member following Dr. Slingerland in her move • Supervise summer students and medical fellows and organized lab meeting schedules

• Target Breast Cancer Cells utilizing an Adenovirus-PKB dominant negative mutant • Perform adenovirus transductions and proliferation studies in breast cancer cell lines